- Buformin
-
- $1980.00
-
2026-04-20
- CAS:692-13-7
- Purity:
- Supply Ability: 10g
|
| | 1-butylbiguanide Basic information |
| | 1-butylbiguanide Chemical Properties |
| Melting point | 174-176 °C | | Boiling point | 271.89°C (rough estimate) | | density | 1.0291 (rough estimate) | | refractive index | 1.8070 (estimate) | | pka | 12.27±0.10(Predicted) | | InChI | InChI=1S/C6H15N5/c1-2-3-4-10-6(9)11-5(7)8/h2-4H2,1H3,(H6,7,8,9,10,11) | | InChIKey | XSEUMFJMFFMCIU-UHFFFAOYSA-N | | SMILES | C(=N)(NCCCC)NC(=N)N |
| | 1-butylbiguanide Usage And Synthesis |
| Uses | Buformin, clinically used for diabetes mellitus, is known to improve resistance to insulin in patients. It suppresses the expression of glyceraldehyde 3-phosphate dehydrogenase | | Definition | ChEBI: Buformin is a member of the class of biguanides that is biguanide substituted by a butyl group at position 1. It is an antidiabetic drug with potential antitumor effect. It has a role as a hypoglycemic agent, a geroprotector, a radiosensitizing agent, an antineoplastic agent and an antiviral agent. It is functionally related to a biguanide. | | Brand name | Adebit;Andebit;Andelit;Andere;Biforon;Bigunal;Biquinal;Bs-5892;Bufonamin;Bulbonin;Diabrin;Dutformin;Gliporal;Insulamin;Krebon;Panformin;Silubin retard;Sindiatil;Tidemol retard;Ziavetine. | | World Health Organization (WHO) | Buformin is an analogue of phenformin. See WHO comment for
phenformin.
(Reference: (WHODI) WHO Drug Information, 2, 4, 1977) | | in vivo | Buformin (oral administation; 7.6mmol/kg of chow; 7 days) exhibits significantly reduced tumor volumes and weights, andhinders mammary morphogenesis and proliferation in MMTV-erbB-2 transgenic mice[1] | Animal Model: | Female MMTV-erbB-2 transgenic mice[1] | | Dosage: | 7.6mmol/kg | | Administration: | Oral administation; 7 days | | Result: | Inhibited mammary syngeneic tumor growth in MMTV-erbB-2 transgenic mice. |
|
| | 1-butylbiguanide Preparation Products And Raw materials |
|